I tend to judge companies and CEOs based on the performance of the company. Since we have no revenue, I look at other key indicators to tell me are they doing a good job or not . I have been a shareholder for most of the year . I bought it for the HIV and cancer applications but then came Covid...so here are my observations:
The CEO was smart enough to it buy this drug several years ago. The deal was a steal
The company was in shambles and now has a market cap of over a billion dollars.
It had zero patients in any Covid trial at the time of my purchase
Today they are in a position to get EAMS from the UK and are building a great case for approval for s/c because of the performance of Leronlimab in trial
Cut a deal with Samsung for production of the drug
They have several doctors who have written papers either going thru peer review or have finished and waiting for publication
He swung a deal to get additional funding of over 25 million and apparently has access to more cash if needed for the NASDAQ uplist
They are positioned well in the HIV market and may get that approval in 2021
The drug shows great performance with the blood/brain barrier which can less to some amazing applications in the future
The negatives ?
Communication skills need polishing . Speaks off the top of his head on timeframes which are taken as gospel by shareholders. He has improved over the last month now saying he expects approval at the end of the year instead of picking the most aggressive date possible and using that in his presentations
Cytodyn will announce such things as potential trials with other countries but doesn’t update shareholders unless asked about some of these during a cc..another communication issue
So I look at company performance . We all probably could agree that there are communication issues he can improve on and be more thoughtful about what he says. But in looking at the performance since I have owned the shares, the company is going thru trials very quickly with regards to Covid , a misstep with the BLA with HIV , which by the way , has happened to many large Pharmas , and is dealing with the overhead of being on the OTC.
My believe is he is doing a pretty good job. B+ considering all the issues hitting the company that has only 18 employees
The CEO was smart enough to it buy this drug several years ago. The deal was a steal
The company was in shambles and now has a market cap of over a billion dollars.
It had zero patients in any Covid trial at the time of my purchase
Today they are in a position to get EAMS from the UK and are building a great case for approval for s/c because of the performance of Leronlimab in trial
Cut a deal with Samsung for production of the drug
They have several doctors who have written papers either going thru peer review or have finished and waiting for publication
He swung a deal to get additional funding of over 25 million and apparently has access to more cash if needed for the NASDAQ uplist
They are positioned well in the HIV market and may get that approval in 2021
The drug shows great performance with the blood/brain barrier which can less to some amazing applications in the future
The negatives ?
Communication skills need polishing . Speaks off the top of his head on timeframes which are taken as gospel by shareholders. He has improved over the last month now saying he expects approval at the end of the year instead of picking the most aggressive date possible and using that in his presentations
Cytodyn will announce such things as potential trials with other countries but doesn’t update shareholders unless asked about some of these during a cc..another communication issue
So I look at company performance . We all probably could agree that there are communication issues he can improve on and be more thoughtful about what he says. But in looking at the performance since I have owned the shares, the company is going thru trials very quickly with regards to Covid , a misstep with the BLA with HIV , which by the way , has happened to many large Pharmas , and is dealing with the overhead of being on the OTC.
My believe is he is doing a pretty good job. B+ considering all the issues hitting the company that has only 18 employees
21
